Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spatial heterogeneity in medulloblastoma.

A Sorana Morrissy1,2, Florence M G Cavalli1,2, Marc Remke1,2,3,4,5

  • 1Developmental &Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.

Nature Genetics
|April 11, 2017
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort study.

EClinicalMedicine·2026
Same author

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

Nature cancer·2026
Same author

Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all Ages.

Neuro-oncology·2026
Same author

Integrated biomarker and treatment correlates of prognosis in infant non-WNT/non-SHH medulloblastoma: a multinational retrospective cohort study.

The Lancet. Child & adolescent health·2026
Same author

Author Correction: Multidimensional profiling of heterogeneity in supratentorial ependymomas.

Nature·2026
Same author

Deep Learning of Histopathology Predicts Outcomes After Surgery for Pancreatic Cancer.

JCO clinical cancer informatics·2026
Same journal

Mutational scanning reveals substrate-assisted autoregulation of the WNT destruction complex.

Nature genetics·2026
Same journal

Spatial transcriptomic analyses highlight distinct erythroid niches in mice and humans.

Nature genetics·2026
Same journal

Building up pangenome analysis block by block.

Nature genetics·2026
Same journal

Mutations in splicing factor gene U2AF1 rescue defective oncogene splicing in KRAS-mutant cancers.

Nature genetics·2026
Same journal

Assessing the effect of immune surveillance on clonal expansions in the blood.

Nature genetics·2026
Same journal

Improved heritability partitioning and enrichment analyses using summary statistics with graphREML.

Nature genetics·2026
See all related articles
Summary
This summary is machine-generated.

Spatial heterogeneity in tumors presents challenges for targeted therapies. While medulloblastomas show homogeneous transcriptomes, actionable mutations are often spatially heterogeneous, questioning monotherapy efficacy.

Area of Science:

  • Oncology
  • Genomics
  • Transcriptomics

Background:

  • Spatial heterogeneity in tumors complicates biomarker identification and targeted therapy development.
  • Understanding intratumoral variability is crucial for effective cancer treatment strategies.

Purpose of the Study:

  • To analyze the spatial heterogeneity of transcriptional and genomic profiles in multiregional tumor biopsies.
  • To assess the implications of spatial heterogeneity for targeted therapy efficacy, particularly in medulloblastoma.

Main Methods:

  • Analysis of transcriptomic and genomic profiles from multiregional biopsies of 35 patients.
  • Comparison of spatial homogeneity in medulloblastomas (MBs) versus high-grade gliomas (HGGs).
  • Evaluation of spatial heterogeneity of actionable somatic mutations across different cancer types.

Related Experiment Videos

Main Results:

  • Medulloblastomas exhibited spatially homogeneous transcriptomes, enabling accurate tumor subgrouping from single biopsies.
  • High spatial heterogeneity of actionable somatic mutations was observed in medulloblastoma, malignant glioma, and renal cell carcinoma.
  • Actionable targets in medulloblastoma were rarely clonal across the entire tumor, raising concerns about monotherapy effectiveness.

Conclusions:

  • Spatially homogeneous transcriptomes in medulloblastoma facilitate subgrouping but do not guarantee target ubiquity.
  • The high spatial heterogeneity of actionable mutations in medulloblastoma challenges the efficacy of single-target monotherapies.
  • Clinical trials for medulloblastoma targeted therapies must verify the spatial ubiquity of target mutations before initiation.